Experimental Conditions
| Experiment No. . | Tumor Line . | Tumor Size Pretreatment Median (range) μL . | Tumor Age Pretreatment (d) . | Cy Dose (mg/kg)/Day Given* . | No. Anti-CD3–Activated Cells Given . | No. of Treatment Courses . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | CD4 . | CD8 . | T Cells . | . |
| 1 | MC38 | 18 (6-32) | 7 | 100/1 | 3.2 × 107 | 3.2 × 107 | 6.5 × 107 | 1 |
| 2 | 3LL | 16 (13-32) | 7 | 150/4 | 5 × 107 | 5 × 107 | — | 1 |
| 3 | 3LL | 23 (13-32) | 16 | 150/4 | 5 × 107† | — | — | 1 |
| MC38 | 4 (4-14) | 8 | 100/4 | 3.1 × 107† | — | — | 2 | |
| 4 | MC38 | 48 (44-75) | 9-11 | 100/2 or 4 | 5.5 × 107 | — | — | 1 |
| Experiment No. . | Tumor Line . | Tumor Size Pretreatment Median (range) μL . | Tumor Age Pretreatment (d) . | Cy Dose (mg/kg)/Day Given* . | No. Anti-CD3–Activated Cells Given . | No. of Treatment Courses . | ||
|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | CD4 . | CD8 . | T Cells . | . |
| 1 | MC38 | 18 (6-32) | 7 | 100/1 | 3.2 × 107 | 3.2 × 107 | 6.5 × 107 | 1 |
| 2 | 3LL | 16 (13-32) | 7 | 150/4 | 5 × 107 | 5 × 107 | — | 1 |
| 3 | 3LL | 23 (13-32) | 16 | 150/4 | 5 × 107† | — | — | 1 |
| MC38 | 4 (4-14) | 8 | 100/4 | 3.1 × 107† | — | — | 2 | |
| 4 | MC38 | 48 (44-75) | 9-11 | 100/2 or 4 | 5.5 × 107 | — | — | 1 |
All mice that received anti-CD3–activated cells were also treated with L-IL-2 (50,000 U IP) for 5 days after cells. Control groups for each experiment are shown in the accompanying figures or are described in Results.
Refers to number of days before cell dose.
Splenocytes were obtained from mice bearing 3LL or MC-38 tumors for 7 days.